EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Neuropsychiatric side effects of mefloquine






New England Journal of Medicine 322(24): 1752-1753

Neuropsychiatric side effects of mefloquine

This letter is from Hoffmann-LaRoche, the manufacturers of mefloquine, in response to an earlier letter in the same journal (ibid., 1989, 321, 1415) describing dizziness, vertigo and dysphoria in 4 of 7 volunteers who took mefloquine (about 15 mg/kg). Registration documents indicate that 24% of patients receiving 750 mg 38% receiving 1000 mg and 96% receiving 1500 mg experience dizziness, and that by splitting the dose the incidence is reduced.

(PDF same-day service: $19.90)

Accession: 001893137

PMID: 2342544

DOI: 10.1056/nejm199006143222416



Related references

Neuropsychiatric side effects after the use of mefloquine. American Journal of Tropical Medicine and Hygiene 45(1): 86-91, 1991

Neuropsychiatric side effects of mefloquine in Africans. Transactions of the Royal Society of Tropical Medicine and Hygiene 87(4): 462-463, 1993

Cognitive and neuropsychiatric side effects of mefloquine. Journal of Neuropsychiatry and Clinical Neurosciences 13(2): 302-302, 2001

Neuropsychiatric side effects of malarial prophylaxis with mefloquine. Harefuah 137(1-2): 25-27, 87, July, 1999

Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam). Harefuah 137(1-2): 25-7, 87, 2000

Long-lasting neuropsychiatric side-effects following mefloquine prophylaxis. A case after six weeks of initiating and lasting six months. Ugeskrift for Laeger 161(10): 1422-1423, 1999

Neuropsychiatric adverse effects of mefloquine What do we know and what should we do?. CNS Drugs 11(1): 1-8, 1999

MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clinical Pharmacology and Therapeutics 80(4): 367-374, 2006

Biased measurement of neuropsychiatric adverse effects of pediatric mefloquine treatment. Pediatric Infectious Disease Journal 31(1): 102; Author Reply 102-3, 2012

Mefloquine: neuropsychiatric adverse effects are often severe and persistent long after withdrawal of the drug. Ugeskrift for Laeger 160(16): 2413-2413, 1998